PriceTargets.com logo

DICE Therapeutics - DICE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$47.55 As of 08/14/2023 01:00 AM ET
+0 (0.00%)
Get New DICE Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DICE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DICE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for DICE Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $47.55.

This chart shows the closing price for DICE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in DICE Therapeutics. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/9/2023HC WainwrightReiterated RatingNeutral$48.00
6/21/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform
6/21/2023GuggenheimDowngradeBuy ➝ Neutral
6/21/2023HC WainwrightDowngradeBuy ➝ Neutral
6/20/2023Leerink PartnersDowngradeOutperform ➝ Market Perform
6/20/2023Stifel NicolausDowngradeBuy ➝ Hold
6/20/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
6/20/2023Evercore ISIDowngradeOutperform
6/20/2023Wells Fargo & CompanyBoost Target$38.00 ➝ $48.00
5/24/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$38.00
5/22/2023Canaccord Genuity GroupInitiated CoverageBuy$71.00
3/31/2023Needham & Company LLCInitiated CoverageBuy$56.00
3/16/2023HC WainwrightReiterated RatingBuy$60.00
3/8/2023HC WainwrightReiterated RatingBuy$60.00
3/1/2023TD CowenInitiated CoverageOutperform
3/1/2023CowenInitiated CoverageOutperform
3/1/2023CowenInitiated CoverageOutperform
11/15/2022GuggenheimInitiated CoverageBuy$65.00
10/11/2022Bank of AmericaBoost Target$34.00 ➝ $62.00
10/11/2022Leerink PartnersBoost TargetOutperform ➝ Outperform$46.00 ➝ $77.00
10/11/2022HC WainwrightBoost TargetBuy$40.00 ➝ $60.00
10/11/2022Cantor FitzgeraldBoost Target$36.00 ➝ $68.00
10/11/2022Evercore ISIBoost Target$45.00 ➝ $75.00
10/11/2022Stifel NicolausBoost Target$37.00 ➝ $54.00
9/14/2022Cantor FitzgeraldInitiated CoverageOverweight$36.00
9/6/2022Stifel NicolausInitiated CoverageBuy$37.00
7/18/2022HC WainwrightInitiated CoverageBuy$40.00
10/11/2021Leerink PartnersInitiated CoverageOutperform$46.00
10/11/2021Bank of AmericaInitiated CoverageBuy$41.00
10/11/2021Evercore ISIInitiated CoverageOutperform$60.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

DICE Therapeutics logo
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $47.55
Low: $47.55
High: $47.55

50 Day Range

MA: $47.31
Low: $46.62
High: $47.55

52 Week Range

Now: $47.55
Low: $15.08
High: $47.90

Volume

N/A

Average Volume

1,028,719 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of DICE Therapeutics?

The following equities research analysts have issued reports on DICE Therapeutics in the last twelve months:
View the latest analyst ratings for DICE.

What is the current price target for DICE Therapeutics?

0 Wall Street analysts have set twelve-month price targets for DICE Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for DICE Therapeutics in the next year.
View the latest price targets for DICE.

What is the current consensus analyst rating for DICE Therapeutics?

DICE Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DICE.

What other companies compete with DICE Therapeutics?

Other companies that are similar to DICE Therapeutics include Scholar Rock, Centessa Pharmaceuticals, Bausch Health Companies, Prevail Therapeutics and Monte Rosa Therapeutics. Learn More about companies similar to DICE Therapeutics.

How do I contact DICE Therapeutics' investor relations team?

DICE Therapeutics' physical mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-566-1420 and its investor relations email address is [email protected]. The official website for DICE Therapeutics is www.dicemolecules.com. Learn More about contacing DICE Therapeutics investor relations.